Cargando…

Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study

Developing effective interventions for preventing first episode psychosis have been an important research focus in the last decade. Cognitive behavioral therapy is a currently indicated treatment for people at ultra-high risk of psychosis, however, access and resource issues limit its delivery withi...

Descripción completa

Detalles Bibliográficos
Autores principales: Parker, Sophie Kate, Mulligan, Lee D., Milner, Philip, Bowe, Samantha, Palmier-Claus, Jasper E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978773/
https://www.ncbi.nlm.nih.gov/pubmed/32010004
http://dx.doi.org/10.3389/fpsyg.2019.02741
_version_ 1783490769657528320
author Parker, Sophie Kate
Mulligan, Lee D.
Milner, Philip
Bowe, Samantha
Palmier-Claus, Jasper E.
author_facet Parker, Sophie Kate
Mulligan, Lee D.
Milner, Philip
Bowe, Samantha
Palmier-Claus, Jasper E.
author_sort Parker, Sophie Kate
collection PubMed
description Developing effective interventions for preventing first episode psychosis have been an important research focus in the last decade. Cognitive behavioral therapy is a currently indicated treatment for people at ultra-high risk of psychosis, however, access and resource issues limit its delivery within the NHS. Treatments which partial out potential active ingredients and are aimed at a range of psychological difficulties seen within this population have the potential to be more efficacious and efficient. We conducted a single-arm exploratory pilot trial, designed to investigate the feasibility and acceptability of Metacognitive therapy for individuals at ultra-high risk (UHR) of developing psychosis. Trial uptake was good, with 11 out of 12 referred individuals meeting for an eligibility assessment (one individual was excluded prior to the assessment). Of these, 10 individuals were eligible and included in the trial. Retention to treatment was high with 80% treatment adherence gained and an overall average of 8 sessions completed. All participants were offered follow-up assessments immediately post-treatment and at 6 months, which comprised measures of psychotic like experiences, anxiety and depression, and metacognitive processes implicated in the model. Retention to the post-treatment (12-week) follow-up was good, with 80% completion; however retention to the 6-month follow-up was lower at 60%. Clinically significant results were observed in psychotic like experiences, anxiety, depression and functioning with medium to large effect sizes. Measures related to beliefs and processes targeted within MCT showed clinically significant change with medium to large effect sizes. Our results suggest that MCT based upon a specific metacognitive model for individuals meeting ARMS criteria may be an important treatment target and warrants further attention. Limitations and possible focuses for future research are discussed. Registration: ISRCTN53190465 http://www.isrctn.com/ISRCTN53190465.
format Online
Article
Text
id pubmed-6978773
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69787732020-02-01 Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study Parker, Sophie Kate Mulligan, Lee D. Milner, Philip Bowe, Samantha Palmier-Claus, Jasper E. Front Psychol Psychology Developing effective interventions for preventing first episode psychosis have been an important research focus in the last decade. Cognitive behavioral therapy is a currently indicated treatment for people at ultra-high risk of psychosis, however, access and resource issues limit its delivery within the NHS. Treatments which partial out potential active ingredients and are aimed at a range of psychological difficulties seen within this population have the potential to be more efficacious and efficient. We conducted a single-arm exploratory pilot trial, designed to investigate the feasibility and acceptability of Metacognitive therapy for individuals at ultra-high risk (UHR) of developing psychosis. Trial uptake was good, with 11 out of 12 referred individuals meeting for an eligibility assessment (one individual was excluded prior to the assessment). Of these, 10 individuals were eligible and included in the trial. Retention to treatment was high with 80% treatment adherence gained and an overall average of 8 sessions completed. All participants were offered follow-up assessments immediately post-treatment and at 6 months, which comprised measures of psychotic like experiences, anxiety and depression, and metacognitive processes implicated in the model. Retention to the post-treatment (12-week) follow-up was good, with 80% completion; however retention to the 6-month follow-up was lower at 60%. Clinically significant results were observed in psychotic like experiences, anxiety, depression and functioning with medium to large effect sizes. Measures related to beliefs and processes targeted within MCT showed clinically significant change with medium to large effect sizes. Our results suggest that MCT based upon a specific metacognitive model for individuals meeting ARMS criteria may be an important treatment target and warrants further attention. Limitations and possible focuses for future research are discussed. Registration: ISRCTN53190465 http://www.isrctn.com/ISRCTN53190465. Frontiers Media S.A. 2020-01-17 /pmc/articles/PMC6978773/ /pubmed/32010004 http://dx.doi.org/10.3389/fpsyg.2019.02741 Text en Copyright © 2020 Parker, Mulligan, Milner, Bowe and Palmier-Claus. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Psychology
Parker, Sophie Kate
Mulligan, Lee D.
Milner, Philip
Bowe, Samantha
Palmier-Claus, Jasper E.
Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
title Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
title_full Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
title_fullStr Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
title_full_unstemmed Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
title_short Metacognitive Therapy for Individuals at High Risk of Developing Psychosis: A Pilot Study
title_sort metacognitive therapy for individuals at high risk of developing psychosis: a pilot study
topic Psychology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6978773/
https://www.ncbi.nlm.nih.gov/pubmed/32010004
http://dx.doi.org/10.3389/fpsyg.2019.02741
work_keys_str_mv AT parkersophiekate metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy
AT mulliganleed metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy
AT milnerphilip metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy
AT bowesamantha metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy
AT palmierclausjaspere metacognitivetherapyforindividualsathighriskofdevelopingpsychosisapilotstudy